Register for our free email digests:
Latest From WaferGen Biosystems Inc.
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October 2015.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
- Antisense, Oligonucleotides
- Large Molecule
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Adynxx Inc.
- Senior Management
Rick Orr, Pres. & CEO
Julien Mamet, PhD, CSO
Donald C Manning, MD, PhD, CMO
Scoyy Harris, VP, Reg. Affairs & Product Dev.
- Contact Info
Phone: (415) 512-7740
100 Pine St.
San Francisco, CA 94111
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.